BerandaHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Tutup sebelumnya
€25,85
Rentang hari
€25,67 - €25,67
Rentang tahun
€19,52 - €36,69
Kapitalisasi pasar
3,58 M USD
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | — | — |
Biaya operasional | 126,19 jt | 28,63% |
Laba bersih | -125,30 jt | -357,42% |
Margin laba bersih | — | — |
Penghasilan per saham | -1,02 | -326,67% |
EBITDA | -121,67 jt | -339,34% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 520,91 jt | 8,30% |
Total aset | 955,15 jt | 7,16% |
Total liabilitas | 459,74 jt | 7,87% |
Total ekuitas | 495,40 jt | — |
Saham yang beredar | 124,20 jt | — |
Harga terhadap reservasi | 6,63 | — |
Tingkat pengembalian aset | -39,90% | — |
Pengembalian modal | -43,18% | — |
Arus Kas
Perubahan bersih tunai
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -125,30 jt | -357,42% |
Kas dari operasi | -92,38 jt | -191,68% |
Tunai dari investasi | -268,94 jt | -645,70% |
Tunai dari pembiayaan | 430,78 jt | 82.741,73% |
Perubahan bersih tunai | 69,49 jt | 203,27% |
Arus kas bebas | -91,82 jt | -262,49% |
Tentang
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Didirikan
1 Jan 2004
Kantor pusat
Situs
Karyawan
525